Anaptysbio, Inc (ANAB): Shareholders' Equity
$37.21M
As of 2025-12-31
$12.75M
As of 2026-03-31
-47.8%
3-year compound annual growth
-37.7%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $37.21M | -47.5% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $70.87M | -19.6% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $88.10M | -66.4% | 2026-03-03, Balance as of period end |
| 2022-12-31 | $262.10M | -26.5% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $356.43M | -10.2% | 2024-03-11, Balance as of period end |
| 2020-12-31 | $396.73M | -2.0% | 2023-03-01, Balance as of period end |
| 2019-12-31 | $405.01M | -16.7% | 2022-03-07, Balance as of period end |
| 2018-12-31 | $486.37M | +58.1% | 2021-02-25, Balance as of period end |
| 2017-12-31 | $307.58M | n/m | 2020-03-02, Balance as of period end |
| 2016-12-31 | -$38.25M | n/m | 2019-02-28, Balance as of period end |
| 2015-12-31 | -$35.18M | n/a | 2018-03-05, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $37.21M | -47.5% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $32.61M | n/m |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $130.34M | +41.5% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $303.13M | -47.0% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $631.00M | +30.1% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $1.02B | -3.4% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $327.19M | -39.2% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $364.05M | -13.6% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $459.28M | -5.5% |
Compare ANAB, AKBA, PBYI, KROS side by side · Screen every company in Pharmaceutical Preparations ↗